Several asset transfers within a week, drug companies began to lose weight at the end of the year

[industry trends of pharmaceutical network] on December 13, Kangzhi pharmaceutical announced that the board of directors had deliberated and approved the proposal for the sale of idle assets on the same day The assets to be sold are the basement of Hong Kong and Macao industrial building, yongwan Industrial Zone, Xiuying District, Haikou City, and the part on the first floor, the part on the second floor and the third to sixth floors It is reported that the total area of the above property is 8807.35 square meters, worth 45.17 million yuan It is worth noting that this is not Kangzhi pharmaceutical's first sale of real estate As early as May 28 and June 24 this year, Kangzhi pharmaceutical has sold the real estate twice in succession, and also issued a notice on August 27, saying that it will turn the company's own real estate into investment real estate for "rental to obtain income" In fact, from the past year's performance, Kangzhi pharmaceutical's selling this time is not unexpected The author found that the net profit of Kangzhi pharmaceutical in the first three quarters after deducting non profits was negative 4.6963 million yuan, and the net profit turned to profit of 1.6573 million yuan The net profit attributable to the shareholders of the listed company ranges from 800000 yuan to 3500000 yuan, down 92.30% to 98.24% year on year Among them, it is estimated that from July to September, the net loss attributable to the shareholders of the listed company will be 2.8 million yuan to 5.5 million yuan In addition to the continuous decline in product sales and the increase in advertising expenses, another major reason for the impact on the performance of Kangzhi pharmaceutical is that most of its wholly-owned subsidiaries and holding subsidiaries have suffered losses to varying degrees As of the end of 2018, Kangzhi pharmaceutical has 12 wholly-owned subsidiaries, 1 holding subsidiary and 1 joint-stock company Statistics show that eight of the above companies lost money last year Therefore, as a whole, Kangzhi pharmaceutical's resale of real estate is really a way to save the performance In fact, near the end of the year, Kangzhi pharmaceutical industry is not the only one to choose to sell For example, on December 14, in order to effectively activate the company's stock assets, focus on the main pharmaceutical industry and reduce the company's capital pressure, fosci pharmaceutical plans to transfer the two land located at No 2, Daijiazhuang, Anning District, Lanzhou City, and the south side of Zhonghai square, Mogao Avenue, Anning District, Lanzhou City, to fosci Pharmaceutical Group, the controlling shareholder, at a price of 103 million yuan On December 13, Guangxi intercontinental, a wholly-owned subsidiary of Sihuan biology, transferred its multi land contracted forest and corresponding forest land use right to 60000 forest farms, with the transfer price of RMB 171 million In addition, in addition to reducing the company's capital pressure to sell real estate, there are also pharmaceutical companies that start to accelerate the divestiture of non core assets and businesses based on their strategic development needs For example, in order to further focus on the pharmaceutical industry business and enhance the core competitiveness, Tianshili also sold its holding subsidiary with an annual revenue of more than 10 billion in recent days Although most pharmaceutical companies attribute the reason for selling assets to optimizing resource allocation, in the view of the insiders, in addition to the real business adjustment, the enterprise selling assets is more likely to hope to make the annual report performance better through asset sale Through the sale of equity, land and use rights and other assets is one of the common ways for listed companies to increase their performance In fact, behind the subtraction of pharmaceutical companies in recent years, it is also inseparable from the national policies to encourage the development of innovative drugs, the consistency evaluation of generic drugs, and the impact of the pharmaceutical environment such as volume purchase In the view of the industry, under the domestic environment of encouraging innovation and R & D, it will become a trend for domestic pharmaceutical enterprises to carry out industrial layout according to their own development needs In the future, more and more enterprises will make targeted industrial acquisitions according to their own development At the same time, more enterprises will sell their assets that do not conform to their own strategic development, so as to obtain some funds to focus on the company's main business development.